NASDAQ: ACHVAchieve Life Sciences Inc Stock
$2.60+0.18 (+7.44%)
Updated Apr 30, 2025
ACHV Price
$2.60
Fair Value Price
$0.09
Market Cap
$90.18M
52 Week Low
$1.84
52 Week High
$5.59
P/E
-2.1x
P/B
4.32x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$39.83M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.85
Operating Cash Flow
-$30M
Beta
0.94
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ACHV Overview
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ACHV's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ACHV
Ranked#447 of 462
Ranked#447 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important ACHV news, forecast changes, insider trades & much more!
ACHV News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ACHV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACHV ($2.60) is overvalued by 2,883.36% relative to our estimate of its Fair Value price of $0.09 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ACHV ($2.60) is not significantly undervalued (2,883.36%) relative to our estimate of its Fair Value price of $0.09 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ACHV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACHV due diligence checks available for Premium users.
Valuation
ACHV fair value
Fair Value of ACHV stock based on Discounted Cash Flow (DCF)
Price
$2.60
Fair Value
$0.09
Overvalued by
2,883.36%
ACHV ($2.60) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACHV ($2.60) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACHV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ACHV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.1x
Industry
-162.28x
Market
29.18x
ACHV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.32x
Industry
4.45x
ACHV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACHV's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.4M
Profit Margin
0%
ACHV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$38.6M
Liabilities
$17.7M
Debt to equity
0.85
ACHV's short-term assets ($36.47M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACHV's short-term assets ($36.47M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACHV's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ACHV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.2M
Investing
$11.7M
Financing
$682.0k
ACHV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACHV vs Biotech Stocks
Achieve Life Sciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.